Literature DB >> 1904113

Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.

Y Kumagae1, Y Matsui, N Iwata.   

Abstract

Levels of monoamines and their metabolites were determined in the cortex, hippocampus, and striatum of rats killed by microwave irradiation. Moclobemide (20 mg/kg, p.o.) and clorgyline (10 mg/kg, p.o.), type A monoamine oxidase (MAO-A) inhibitors, increased the levels of normetanephrine (NM) and 3-methoxytyramine (3MT) and decreased those of 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5HIAA) in almost all three regions. Deprenyl (10 mg/kg, p.o.), a type B monoamine oxidase inhibitor, however, little affected monoamine and metabolite levels in all regions. The maximum effects of RS-8359 (10 mg/kg, p.o.) were obtained at 2 to 6 hr after administration, when the levels of norepinephrine (NE), NM, 3MT, and serotonin (5HT) in all regions and dopamine (DA) in the striatum increased, while DOPAC and HVA levels decreased. The levels of monoamines and metabolites had returned to normal by 20 hr after administration. Dose-dependency of the effects of RS-8359 on monoamine metabolites was observed at doses up to 30 mg/kg (p.o.) at 1 and 6 hr after administration. In conclusion, NE, DA, and 5HT are exclusively or preferentially deaminated by MAO-A in the cortex, hippocampus, and striatum of rats, and RS-8359 exhibits a reversible MAO-A inhibitory action in all three regions tested in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904113     DOI: 10.1254/jjp.55.121

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  11 in total

1.  Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment.

Authors:  John F Cryan; Michelle E Page; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

2.  Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.

Authors:  Kevin R Krull; Deepa Bhojwani; Heather M Conklin; Deqing Pei; Cheng Cheng; Wilburn E Reddick; John T Sandlund; Ching-Hon Pui
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

Review 3.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

Review 4.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

5.  MAO activity in serotonergic endings of rat major cerebral arteries.

Authors:  A L López de Pablo; M Ajubita; M C F Criado; E J Marco
Journal:  J Physiol Biochem       Date:  2004-03       Impact factor: 4.158

6.  Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359.

Authors:  H Miura; M Naoi; D Nakahara; T Ohta; T Nagatsu
Journal:  J Neural Transm Gen Sect       Date:  1993

7.  Quantitative distribution of rat brain monoamine oxidase A by [14C]clorgyline autoradiography.

Authors:  Y Kondoh; M Murakami; W Yin; S Mizusawa; H Nakamichi; K Nagata
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 8.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Authors:  N P Nair; S K Ahmed; N M Kin
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

Review 9.  Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.

Authors:  Tapan Behl; Dapinder Kaur; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Gokhan Zengin; Felicia Liana Andronie-Cioara; Mirela Marioara Toma; Simona Bungau; Adrian Gheorghe Bumbu
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

Review 10.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.